Health Canada Can Now Ask for New Data Mid-Review: The Access Consortium Work-Sharing Pilot Explained

On 14 September 2026, Health Canada published a notice that quietly changes the risk calculus for every sponsor filing a work-sharing joint review. Under a new pilot, Health Canada can now request new and updated safety and efficacy data during the review of an Access Consortium submission, rather than issuing a deficiency notice and adding a full review cycle. The change took effect the day the notice was published, for both new and ongoing submissions.

For innovator and generic sponsors, this is a rare piece of good news wrapped in a procedural detail. Used well, the mid-review data request can keep a submission alive that would previously have drawn a notice of deficiency or a notice of non-compliance. Used carelessly, it becomes a trap, because the notice sets hard boundaries on what data Health Canada will accept. This article explains the pilot, the boundaries, what stays the same, and how to prepare. It sits alongside our guide to the new 90-day limit on NOD and NON extensions for generic drugs.

Executive Summary

Health Canada has launched a pilot allowing it to request new and updated data during the review of Access Consortium work-sharing submissions. The pilot took effect 14 September 2026 and applies to new and ongoing submissions under the New Active Substances Work-Sharing Initiative for innovators and the Generic Medicines Work-Sharing Initiative for generics. Requests come through the consolidated list of questions, and this can avoid a notice of deficiency or a notice of non-compliance. The flexibility is bounded: the data must respond to the request and must not include unsolicited information, must not change the dosage form or formulation, must not expand or propose a new indication or route of administration, must not change dosage or route beyond clarifying existing instructions, and must not change warnings, precautions or contraindications in a way that expands the exposed population. Submissions must still be complete at filing, and pause-the-clock provisions still apply.

What the Access Consortium is

The Access Consortium is a coalition of like-minded medium-sized regulatory authorities, including Health Canada, that collaborate on the review of drug submissions to share work and reduce duplication. What it means for you: when you file a submission as a work-sharing joint review, several regulators assess it in parallel using a shared evaluation. What to do: understand which of the two initiatives your submission falls under, because this pilot applies to both. Learn more from the Access Consortium overview.

What changed: requesting new data mid-review

What it is: Health Canada may now request new and updated data needed to assess the safety and efficacy of a drug during a joint review, rather than only at the start. Why it matters: previously, a data gap identified during review often led to a deficiency notice and another review cycle. What to do: build your submission so that you can respond to a mid-review request quickly and within scope, because the request is an opportunity to keep the file moving, not an invitation to expand it.

Health Canada frames this as red tape reduction and better alignment with its Access Consortium partners, all while maintaining the safety, efficacy and quality standards for the products under review. The pilot will inform whether similar flexibility is used elsewhere in the future.

How the request works: the list of questions

What it is: Health Canada will request new data through the consolidated list of questions, known as the LOQ, during the review cycle. Why it matters: routing a data request through the LOQ can avoid issuing a notice of deficiency or a notice of non-compliance, each of which would otherwise cost time. What to do: treat the LOQ response as a high-stakes, time-bound deliverable, because how completely and quickly you answer it determines whether the pilot helps you or not.

Health Canada notes that it will only issue a notice of deficiency or non-compliance without a prior LOQ request in rare cases, and may still issue one where a complete LOQ response is not provided within the stated timelines. The submission processes, including pause-the-clock, remain governed by the guidance on management of drug submissions and applications.

The four boundaries on new data

What it is: the notice sets clear limits on what the new or updated data may contain. Why it matters: data that crosses a boundary will not be accepted through this route, and pushing it can undermine the very submission you are trying to save. What to do: before you send anything, confirm the data responds to the request, contains no unsolicited information, and stays inside all four limits below.

• It must not include changes to the drug's dosage form or formulation
• It must not include changes that would expand or propose a new indication or route of administration
• It must not change the dosage and route of administration, other than clarifying the existing instructions
• It must not change warnings, precautions and contraindications in a way that expands the exposed population or increases individual exposure

The overarching rule is simple: the information must respond to Health Canada's request and should not include unsolicited information. A response that answers the question precisely is the response that works.

What stays the same

This is a flexibility, not a relaxation of the standard. Access Consortium work-sharing submissions must still be complete at filing. The evaluation plan, the timelines, and the requirements to meet the conditions of a work-sharing submission remain unchanged. Submission requirements under the Food and Drug Regulations continue to apply, as do the pause-the-clock provisions and the unsolicited information rules set out in the management of drug submissions and applications guidance.

In other words, you cannot file thin and plan to fill the gaps mid-review. The pilot rewards a complete, well-built submission that can then respond precisely to a targeted question, which is the same discipline that keeps a notice of compliance with conditions pathway on track.

Who is affected: NASWSI and GMWSI

The pilot applies to submissions filed as a work-sharing joint review under two Access Consortium initiatives. Confirm which one covers your product, because the boundaries and the LOQ discipline apply identically to both.

Generic sponsors already navigating tighter Canadian timelines should read this alongside the 90-day limit on NOD and NON extensions and the generic prioritisation and domestic manufacturing pilot. Innovators weighing global filing strategy can compare this with international reliance approaches used elsewhere.

A worked example: a question, not a cycle

Consider a generic sponsor filing under the Generic Medicines Work-Sharing Initiative. Mid-review, Health Canada identifies that one impurity in the stability data needs an additional bridging result to confirm the proposed shelf life. Before this pilot, that single gap could have drawn a notice of deficiency, resetting part of the clock and adding weeks or months. Under the pilot, Health Canada can raise the point in the consolidated list of questions, and the sponsor supplies the bridging result inside the response window. The submission continues without a deficiency notice.

Now change one detail. Suppose the same sponsor, while answering, decides to also update the formulation to a slightly different excipient grade. That addition crosses a boundary, because it is a change to the formulation and it was not requested. It risks turning a clean response into one Health Canada cannot accept through this route. The lesson is that the pilot rewards precision. Answer the question that was asked, supply only the data that responds to it, and hold every other change for the appropriate submission type. That discipline is what converts a mid-review request into a saved cycle rather than a new problem.

What sponsors should do now

• Confirm whether your live submissions are filed as NASWSI or GMWSI work-sharing joint reviews, since ongoing submissions are covered
• Brief your regulatory and medical writing teams that a mid-review LOQ may now request new or updated data
• Set an internal LOQ response protocol with a named owner, a target turnaround, and a scope gate against the four boundaries
• Keep your submission complete at filing; the pilot does not change the completeness requirement
• Map your pause-the-clock assumptions so a mid-review request does not surprise your timeline
• Document your eligibility and scope rationale so a response can be assembled quickly and defensibly

Compliance checklist

Use this list to make your work-sharing submissions ready for a mid-review data request.

• Submission completeness verified at filing against the Food and Drug Regulations
• Initiative confirmed: NASWSI for innovator, GMWSI for generic
• LOQ response SOP with a named owner and a defined turnaround
• Scope gate that screens any new data against the four boundaries before it is sent
• Control that removes unsolicited information from any response
• Pause-the-clock tracking aligned to the management of drug submissions guidance
• Version control and audit trail for data updated during review
• Escalation path for cases where a complete response cannot be met within the stated timeline

Common mistakes

• Treating the pilot as permission to file an incomplete submission and fill gaps later
• Sending unsolicited information alongside the requested data
• Slipping a formulation or dosage form change into a mid-review response
• Using the response to expand or propose a new indication or route of administration
• Widening warnings, precautions or contraindications in a way that expands the exposed population
• Missing the LOQ response window, which can still trigger a notice of deficiency or non-compliance

Frequently asked questions

What is the Access Consortium work-sharing pilot?

It is a Health Canada pilot, effective 14 September 2026, that allows Health Canada to request new and updated safety and efficacy data during the review of an Access Consortium work-sharing submission. The aim is to reduce red tape and align with Access Consortium partners while maintaining safety, efficacy and quality standards.

Which submissions does the pilot apply to?

It applies to new and ongoing submissions filed as a work-sharing joint review under the New Active Substances Work-Sharing Initiative for innovators and the Generic Medicines Work-Sharing Initiative for generics.

How will Health Canada request new data?

Through the consolidated list of questions, known as the LOQ, during the review cycle. Routing the request through the LOQ can avoid issuing a notice of deficiency or a notice of non-compliance.

Does the pilot mean my submission can be incomplete at filing?

No. Access Consortium work-sharing submissions must still be complete at filing. The evaluation plan, timelines and work-sharing conditions remain unchanged, and Food and Drug Regulations requirements continue to apply.

What data will Health Canada not accept through this route?

Data that changes the dosage form or formulation, expands or proposes a new indication or route of administration, changes dosage or route beyond clarifying existing instructions, or changes warnings, precautions or contraindications in a way that expands the exposed population. Unsolicited information should not be included.

Can Health Canada still issue a notice of deficiency or non-compliance?

Yes. Health Canada will issue one without a prior LOQ request only in rare cases, and may still issue one where a complete LOQ response is not provided within the stated timelines.

Do pause-the-clock provisions still apply?

Yes. Pause-the-clock provisions and other submission processes in the management of drug submissions and applications guidance continue to apply.

How MFLRC can help

MFLRC supports innovator and generic sponsors across the submission lifecycle, from filing strategy to responding under pressure. For the Access Consortium pilot we help you build submissions that are complete at filing, design an LOQ response protocol that answers the question within scope and on time, and screen any mid-review data against the four boundaries before it is sent. We also provide regulatory strategy retainers, submission-readiness reviews, and Quality Assurance Person support, and we monitor regulatory change so a notice like this one does not catch your team off guard.

If you have a NASWSI or GMWSI submission in review right now, the time to set your LOQ response protocol is before the request arrives, not after.

Conclusion

The Access Consortium mid-review data pilot is a small notice with real leverage. For a well-built submission, it can turn a data gap into a targeted question rather than a lost cycle. For a thin one, it changes nothing, because completeness at filing still governs. The sponsors who benefit will be the ones who treat the list of questions as a rehearsed, scoped, time-bound deliverable, and who keep every mid-review response inside the four boundaries Health Canada has drawn. Set that protocol now, while your submissions are moving.

Sources and references

• Health Canada, Requesting new data for review of Access Consortium work-sharing submissions: Notice (14 September 2026)
• Health Canada, Access Consortium overview
• Health Canada, Guidance on management of drug submissions and applications
• Government of Canada, Red Tape Review